Details
Stereochemistry | ACHIRAL |
Molecular Formula | C28H27NO2S |
Molecular Weight | 441.584 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1(C)CCC(C)(C)C2=C1C=C3SC4=CC=CC=C4N=C(C5=CC=C(C=C5)C(O)=O)C3=C2
InChI
InChIKey=PFGCWQPTOKPRRK-UHFFFAOYSA-N
InChI=1S/C28H27NO2S/c1-27(2)13-14-28(3,4)21-16-24-19(15-20(21)27)25(17-9-11-18(12-10-17)26(30)31)29-22-7-5-6-8-23(22)32-24/h5-12,15-16H,13-14H2,1-4H3,(H,30,31)
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/9435893 | https://www.ncbi.nlm.nih.gov/pubmed/26883505Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/26714014 https://www.ncbi.nlm.nih.gov/pubmed/24916544
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9435893 | https://www.ncbi.nlm.nih.gov/pubmed/26883505
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/26714014 https://www.ncbi.nlm.nih.gov/pubmed/24916544
HX630 is a synthetic RXR pan-agonist. HX-630 has bein shown to exert anti-proliferative and pro-apoptotic effects in murine pituitary corticotroph tumor AtT20 cells, making HX-630 a new therapeutic candidate for Cushing’s disease. It might also serve as potential pharmacological tool for treating retina degenerative diseases and Alzheimer's disease.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2363070 |
|||
Target ID: CHEMBL2061 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9435893 |
900.0 nM [Ki] | ||
Target ID: CHEMBL1870 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9435893 |
400.0 nM [Ki] | ||
Target ID: CHEMBL2004 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9435893 |
620.0 nM [Ki] | ||
Target ID: CHEMBL2008 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9435893 |
320.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26714014
Mice: 5 mg/kg/day, injected intraperitonealy 3 times a week for 3 weeks
Route of Administration:
Intraperitoneal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26714014
HX-630 significantly suppressed AtT20 cell proliferation at 10 uμM
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
188844-52-2
Created by
admin on Sat Dec 16 09:00:08 GMT 2023 , Edited by admin on Sat Dec 16 09:00:08 GMT 2023
|
PRIMARY | |||
|
DTXSID80172254
Created by
admin on Sat Dec 16 09:00:08 GMT 2023 , Edited by admin on Sat Dec 16 09:00:08 GMT 2023
|
PRIMARY | |||
|
9889522
Created by
admin on Sat Dec 16 09:00:08 GMT 2023 , Edited by admin on Sat Dec 16 09:00:08 GMT 2023
|
PRIMARY | |||
|
N564S742U1
Created by
admin on Sat Dec 16 09:00:08 GMT 2023 , Edited by admin on Sat Dec 16 09:00:08 GMT 2023
|
PRIMARY |
ACTIVE MOIETY